ImClone Systems State-of-the-Art Manufacturing Facility Receives FDA Approval for Multi-Product Biologics Production ImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, announced that it has received approval from the Food and Drug Administration for its state-of-the-art "BB50" manufacturing facility to manufacture multiple products. This approval significantly expands ImClone's total available production volume capacity for its proprietary pipeline of novel antibodies, which are now entering late-stage clinical development. [more...]
